IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Stock Down 2.2 %

Shares of NASDAQ:IDXX opened at $374.01 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 1.68. The company has a fifty day simple moving average of $370.83 and a 200 day simple moving average of $437.92. The firm has a market cap of $31.14 billion, a PE ratio of 48.26, a price-to-earnings-growth ratio of 5.09 and a beta of 1.14. IDEXX Laboratories has a 12-month low of $318.50 and a 12-month high of $695.18.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $500.00 to $420.00 in a research note on Monday, August 8th. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $603.00 to $573.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. Bank of America cut shares of IDEXX Laboratories from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. The Goldman Sachs Group raised shares of IDEXX Laboratories from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $530.00 to $435.00 in a research report on Thursday, July 21st. Finally, Barclays cut their price target on shares of IDEXX Laboratories from $700.00 to $582.00 and set an "overweight" rating on the stock in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $483.57.